The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.
作者信息
Lehrer Steven, Rheinstein Peter H
机构信息
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Severn Health Solutions, Severna Park, Maryland.
出版信息
Cancer. 2020 Jun 1;126(11):2718. doi: 10.1002/cncr.32788. Epub 2020 Feb 19.
Abstract
摘要
相似文献
1
The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.老年前列腺癌患者的5年相对生存率与所有同龄男性的5年生存率相比，差异不显著。
Cancer. 2020 Jun 1;126(11):2718. doi: 10.1002/cncr.32788. Epub 2020 Feb 19.
2
Reply to The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.回复：老年前列腺癌患者的5年相对生存率与所有同龄男性的5年生存率无显著差异。
Cancer. 2020 Jun 1;126(11):2718-2719. doi: 10.1002/cncr.32791. Epub 2020 Feb 19.
3
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.70岁以上男性在前列腺特异性抗原早期和晚期阶段患前列腺癌的风险更高，生存率更低。
J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034. Epub 2009 Sep 16.
4
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.前列腺特异性抗原检出的低危前列腺癌的初始管理和前列腺癌死亡风险。
BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.
5
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.前列腺癌筛查中年龄校正后的前列腺特异性抗原及前列腺特异性抗原变化率切点
J Urol. 2007 Feb;177(2):499-503; discussion 503-4. doi: 10.1016/j.juro.2006.09.063.
6
7
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.2012 年美国预防服务工作组建议不鼓励基于前列腺特异性抗原的前列腺癌筛查后，全国前列腺癌筛查率。
J Clin Oncol. 2015 Aug 1;33(22):2416-23. doi: 10.1200/JCO.2015.61.6532. Epub 2015 Jun 8.
8
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.总前列腺特异性抗原低于4 ng/ml的男性的前列腺特异性抗原速率
J Urol. 2007 Dec;178(6):2348-52; discussion 2352-3. doi: 10.1016/j.juro.2007.08.016. Epub 2007 Oct 22.
9
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.血清前列腺特异性抗原值高于100 ng/ml的男性发生远处转移的风险及癌症特异性生存率
J Urol. 2015 Dec;194(6):1594-600. doi: 10.1016/j.juro.2015.07.082. Epub 2015 Jul 17.
10
Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.年龄、良性前列腺增生和癌症对前列腺特异性抗原水平的影响。
Cancer. 2006 Apr 1;106(7):1507-13. doi: 10.1002/cncr.21766.
引用本文的文献
1
Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.关于：美国预防服务工作组建议不进行筛查后5年的前列腺癌发病率
J Natl Cancer Inst. 2020 Oct 1;112(10):1067-1068. doi: 10.1093/jnci/djaa092.
本文引用的文献
1
Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.基于人群的研究：局限性前列腺癌现代临床危险分组的年龄依赖性。
Cancer. 2020 Apr 15;126(8):1691-1699. doi: 10.1002/cncr.32702. Epub 2020 Jan 3.
2
United States life tables, 2002.《2002年美国生命表》
Natl Vital Stat Rep. 2004 Nov 10;53(6):1-38.
Zotero 插件